TY - JOUR
T1 - A Review of the Diagnosis and Treatment of Metastatic Colorectal Cancer
AU - Bien, Jeffrey
AU - Lin, Albert
N1 - Funding Information:
Corresponding Author: Deborah Schrag, MD, MPH, 450 Brookline Ave, Boston, MA 02115 ([email protected]). Conflict of Interest Disclosures: Dr Schrag reports receipt of personal fees from Pfizer (speaking engagement), and research funding from the American Association of Cancer Research and serving as a site primary investigator on a study funded by Grail. No other disclosures were reported. 1. Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669-685. doi:10.1001/jama.2021.0106 2. André T, Shiu KK, Kim TW, et al; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207-2218. doi:10.1056/NEJMoa2017699 3. Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30(7):1096-1103. doi:10.1093/annonc/mdz134 4. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145-164. doi:10.3322/caac.21601 5. Bui A, Yang L, Myint A, May FP. Race, ethnicity, and socioeconomic status are associated with prolonged time to treatment after a diagnosis of colorectal cancer: a large population-based study. Gastroenterology. 2021;160(4):1394-1396.e3. doi:10.1053/j.gastro.2020.10.010
PY - 2021/6/15
Y1 - 2021/6/15
UR - https://www.scopus.com/pages/publications/85107984413
U2 - 10.1001/jama.2021.6021
DO - 10.1001/jama.2021.6021
M3 - Letter
C2 - 34129003
AN - SCOPUS:85107984413
SN - 0098-7484
VL - 325
SP - 2404
EP - 2405
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 23
ER -